Evidence map›Paper›PMID 27653941›Full record

ArticleThe American journal of case reports2016

Ciprofloxacin Exposure Leading to Fatal Hepatotoxicity: An Unusual Correlation.

Carly Unger, Layth S Al-Jashaami

Open access · hybridAbstract read
In one paragraph

Article in The American journal of case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. A Fatal Case of Ciprofloxacin-induced Fulminant Hepatitis.European journal of case reports in internal medicine · 2020
    Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Carly Unger, Bethel University Physician Assistant Program, Paris, TN, USA.
Layth S Al-JashaamiDepartment of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA.
Banner - University Medical Center Phoenix · USBethel University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Ciprofloxacin is a commonly used fluoroquinolone antibiotic. It is occasionally associated with benign elevations in liver enzymes. Few reports in the literature correlate ciprofloxacin with significant liver injury. We present a fatal case of ciprofloxacin-induced liver failure. CASE REPORT  A 74-year-old female was successfully treated with ciprofloxacin for a urinary tract infection (UTI), but immediately began having new-onset symptoms, including fatigue and nausea. This continued for two months, at which time she presented to the hospital; she was found to have elevated liver enzymes and another UTI. She was treated with ciprofloxacin again for UTI and discharged three days later, following mild improvement. One week later, she returned to another hospital and was found to have more significantly elevated liver function tests and jaundice. Extensive viral and autoimmune panels were unremarkable. Liver biopsy showed cholestatic hepatitis of unclear etiology. The patient was discharged again following a mild decline in liver enzymes. Soon after, the patient was admitted to our institution with similar complaints. Serum transaminases remained elevated, with an increase in alkaline phosphatase and bilirubin. The Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method (CIOMS/RUCAM) scale was found to be 8, outlining a high or definite probability that the ciprofloxacin was the cause of the patient's hepatotoxicity. A one-week course of prednisone for possible hypersensitivity reaction was tried; however, it proved unsuccessful. Palliative care was consulted, and the patient passed away shortly thereafter. CONCLUSIONS This case demonstrates the potential for liver failure from ciprofloxacin. Clinicians should evaluate the possibility of ciprofloxacin-induced hepatotoxicity in a patient presenting with liver injury of unknown etiology. Similarly, it is important to consider this significant effect when a practitioner considers antibiotic choice.

Identifiers

PMID27653941
PMCPMC5036381
OpenAlexW2522770318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.